Aetna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied for missing prior authorization by Aetna?

Q: How long do I have to appeal a Aetna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If the original prescription wasn't run through prior auth, the path is to submit a PA now with a medical-necessity letter — many plans then back-date approval to the date of service.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

HbA1c ≥6.5% per CVS Caremark form 5496-C.

Source policy: Aetna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Aetna angle on Tirzepatide

## Aetna's Prior Authorization Trap for Tirzepatide (Mounjaro) — Reason-Anchored Analysis

When Aetna issues a prior-auth-required denial for tirzepatide, it is not a clinical rejection — it is a procedural gate. The claim never reached medical review. CVS Caremark, Aetna's pharmacy benefit manager, intercepted the NCPDP transaction at the point of sale and returned reject code 75 (Prior Authorization Required) or 76 (Plan Limitations Exceeded). Your appeal must therefore solve a workflow problem first and a clinical problem second.

### The CVS Caremark Channel Is Non-Negotiable

Tirzepatide for type 2 diabetes is adjudicated under Aetna Clinical Policy Bulletin (CPB) 0828 — Antidiabetic Agents and the corresponding CVS Caremark PA form 5496-C, which requires documented HbA1c ≥6.5% drawn within the prior 90 days, ICD-10 E11.x diagnosis, and evidence of metformin trial (or contraindication per CPB 0828 §III.B). Submitting the PA through Availity or the Aetna provider portal will not work — those routes return to Caremark's queue but add 3–5 business days. The correct channel is CoverMyMeds → CVS Caremark PA Department (fax 1-888-487-9257) or the ePA portal at caremark.com/epa. Caremark's published turnaround under 42 CFR §423.568 (if Medicare Part D) or the plan's commercial SLA is 72 hours standard, 24 hours expedited.

### The Two Failure Modes

Most prior-auth-required denials at Aetna trace to one of two defects: (1) the prescriber's office submitted a PA but omitted the HbA1c value or used a lab >90 days old, triggering an auto-reject under Caremark's edit logic; or (2) no PA was ever filed and the pharmacy simply rejected at the counter. Pull the NCPDP reject narrative from the pharmacy — it will explicitly state whether a PA is pending, denied, or never submitted. Without this, you are appealing blind.

### ERISA and State Leverage

For commercial ERISA plans, 29 CFR §2560.503-1(g) requires Aetna to disclose the specific CPB version and form fields that were deficient. Demand the "adverse benefit determination" letter in writing — verbal pharmacy rejections are not appealable until reduced to writing. If Aetna stalls past 30 days on a pre-service appeal, file a parallel complaint with your state DOI (Texas TDI, California DMHC, New York DFS are the most aggressive on PBM delays). For self-funded plans, the DOL EBSA complaint route under 29 USC §1132(a)(1)(B) preserves your standing.

### Tactical Tip

Attach the HbA1c lab report as a discrete PDF (not embedded in chart notes) to the CoverMyMeds submission. Caremark's OCR pipeline indexes discrete attachments faster, and reviewers approve >80% of complete tirzepatide PAs on first pass when the A1c is front-and-center. If the A1c is 6.4%, request a fasting plasma glucose ≥126 mg/dL or 2-hour OGTT ≥200 mg/dL as alternative ADA diagnostic criteria under CPB 0828 §II — Caremark accepts these as equivalent.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Tirzepatide

Other denial reasons for Aetna Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.